Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICAT cataract surgery anti-inflammatory prophylaxis study
2019-004890-21Phase 3Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bromfenac sodium, dexamethasone sodium phosphate, triamcinolone acetonide, ketorolac and phenylephrine in cystoid macular edema (CME) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Change in central subfield mean macular thickness. Started Nov 2020; status: terminated.
02
Drugs
bromfenac sodiumdexamethasone sodium phosphatetriamcinolone acetonideketorolacphenylephrine
03
Conditions
cystoid macular edema (CME)
Beyond the preview
Go deeper on 2019-004890-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004890-21.